Paper19946262
Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
Kojima K and 8 others. Leukemia, 2010. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Papers, record 19946262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19946262
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apoptosis | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Mutation | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Pyridines | Major topic |
| Pyrimidines | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| fms-Like Tyrosine Kinase 3 | Major topic |
| Cell Line, Tumor | |
| Doxorubicin | |
| G1 Phase | |
| Humans | |
| Imidazoles | |
| Myeloid Cell Leukemia Sequence 1 Protein | |
| Piperazines | |
| Proteasome Endopeptidase Complex | |
| bcl-2-Associated X Protein |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA016672 | NIH |
Source NIH RePORTER
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15902208 | An inhibitor of Bcl-2 family proteins induces regression of solid tumours. | Nature | 2005 | https://conductscience.org/library/papers/15902208 | PubMed |
| 2 | 16014563 | MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. | Blood | 2005 | https://conductscience.org/library/papers/16014563 | PubMed |
| 3 | 12951584 | The role of FLT3 in haematopoietic malignancies. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12951584 | PubMed |
| 4 | 11090077 | Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. | Blood | 2000 | https://conductscience.org/library/papers/11090077 | PubMed |
| 5 | 8946930 | Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. | Leukemia | 1996 | https://conductscience.org/library/papers/8946930 | PubMed |
| 6 | 17554384 | BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. | Leukemia | 2007 | https://conductscience.org/library/papers/17554384 | PubMed |
| 7 | 18230792 | Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. | J Natl Cancer Inst | 2008 | https://conductscience.org/library/papers/18230792 | PubMed |
| 8 | 15959528 | Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. | Leukemia | 2005 | https://conductscience.org/library/papers/15959528 | PubMed |
| 9 | 1905840 | p53 mutations in human cancers. | Science | 1991 | https://conductscience.org/library/papers/1905840 | PubMed |
| 10 | 17389404 | Structural insights into the degradation of Mcl-1 induced by BH3 domains. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17389404 | PubMed |
| 11 | 19144992 | A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. | Blood | 2009 | https://conductscience.org/library/papers/19144992 | PubMed |
| 12 | 10679322 | Rsk1 mediates a MEK-MAP kinase cell survival signal. | Curr Biol | 2000 | https://conductscience.org/library/papers/10679322 | PubMed |
| 13 | 17097561 | The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Cancer Cell | 2006 | https://conductscience.org/library/papers/17097561 | PubMed |
| 14 | 14704432 | In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. | Science | 2004 | https://conductscience.org/library/papers/14704432 | PubMed |
| 15 | 16543145 | Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. | Mol Cell | 2006 | https://conductscience.org/library/papers/16543145 | PubMed |
| 16 | 12667443 | p53 has a direct apoptogenic role at the mitochondria. | Mol Cell | 2003 | https://conductscience.org/library/papers/12667443 | PubMed |
| 17 | 17940205 | FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. | Blood | 2008 | https://conductscience.org/library/papers/17940205 | PubMed |
| 18 | 15459012 | A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. | Blood | 2005 | https://conductscience.org/library/papers/15459012 | PubMed |
| 19 | 10713704 | Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. | Oncogene | 2000 | https://conductscience.org/library/papers/10713704 | PubMed |
| 20 | 14726387 | Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. | Blood | 2004 | https://conductscience.org/library/papers/14726387 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31127149 | Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. | Leukemia | 2019 | https://conductscience.org/library/papers/31127149 | PubMed |
| 28727820 | Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells. | PLoS One | 2017 | https://conductscience.org/library/papers/28727820 | PubMed |
| 28530640 | Genetic regulation of the RUNX transcription factor family has antitumor effects. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28530640 | PubMed |
| 28505595 | Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. | Leuk Res | 2017 | https://conductscience.org/library/papers/28505595 | PubMed |
| 28286924 | Treatment of Relapsed/Refractory Acute Myeloid Leukemia. | Curr Treat Options Oncol | 2017 | https://conductscience.org/library/papers/28286924 | PubMed |
| 28211885 | The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. | Blood Cancer J | 2017 | https://conductscience.org/library/papers/28211885 | PubMed |
| 26459177 | Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26459177 | PubMed |
| 26375587 | Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. | PLoS One | 2015 | https://conductscience.org/library/papers/26375587 | PubMed |
| 25231999 | Targeting FLT3 to treat leukemia. | Expert Opin Ther Targets | 2015 | https://conductscience.org/library/papers/25231999 | PubMed |
| 23955073 | PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. | J Mol Med (Berl) | 2013 | https://conductscience.org/library/papers/23955073 | PubMed |
| 23531342 | Targeting p53 by small molecules in hematological malignancies. | J Hematol Oncol | 2013 | https://conductscience.org/library/papers/23531342 | PubMed |
| 23036488 | Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. | Cancer Lett | 2013 | https://conductscience.org/library/papers/23036488 | PubMed |
| 22797419 | FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. | Leukemia | 2013 | https://conductscience.org/library/papers/22797419 | PubMed |
| 21868571 | p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. | Blood | 2011 | https://conductscience.org/library/papers/21868571 | PubMed |
| 21471285 | The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. | Mol Cancer Ther | 2011 | https://conductscience.org/library/papers/21471285 | PubMed |
| 20952518 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. | Haematologica | 2011 | https://conductscience.org/library/papers/20952518 | PubMed |
| 20587003 | Clinical proteomics of myeloid leukemia. | Genome Med | 2010 | https://conductscience.org/library/papers/20587003 | PubMed |
| 20404136 | Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. | Blood | 2010 | https://conductscience.org/library/papers/20404136 | PubMed |
| 20013323 | p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. | Int J Hematol | 2010 | https://conductscience.org/library/papers/20013323 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAX | 581 | PubTator's text mining | https://conductscience.org/library/genes/581 | NCBI Gene |
| BCL2L11 | 10018 | PubTator's text mining | https://conductscience.org/library/genes/10018 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| MCL1 | 4170 | PubTator's text mining | https://conductscience.org/library/genes/4170 | NCBI Gene |
| MDM2 | 4193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
| PMAIP1 | 5366 | PubTator's text mining | https://conductscience.org/library/genes/5366 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19946262
GET https://conductscience.org/api/papers/v1/19946262/references?page=2